5 Key Takeaways

• 1

  Photobiomodulation (PBM) is an FDA-authorized treatment for patients with dry age-related macular degeneration (AMD).

• 2

  PBM uses low-intensity light at specific wavelengths to stimulate cellular activity and improve vision in dry AMD patients.

• 3

  Clinical trials show PBM can improve visual acuity by approximately one line after two years of treatment.

• 4

  Billing for PBM requires specific documentation and coding, including the new Category III CPT code 0936T effective January 2025.

• 5

  Coverage for PBM may vary by payer, necessitating patient waivers when coverage is uncertain or ambiguous.